My laboratory is interested in immunotherapy for cancer, with particular emphasis on the clinical development and application of monoclonal antibodies. Recent work from my group includes a Phase I trial of naptumomab estafenatox, a recombinant fusion protein consisting of a mutated variant of the superantigen staphylococcal enterotoxin E (SEA/E-120) linked to the antigen binding moiety of a monoclonal antibody recognizing the tumor-associated antigen 5T. In addition to developing new monoclonal antibodies, I am conducting clinical trials exploring the immunological responses that occur as a result of cetuximab therapy-associated antibody-dependent cellular cytotoxicity (ADCC)ADCC, with the goal of augmenting these immune responses to achieve improved efficacy of antibody therapy. In addition, I am involved in a number of clinical trials with various other monoclonal antibodies such as cetuximab. My latest lung cancer trial explores the relationship between EGFR and Aurora Kinase in lung cancer.